title: The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.
authors.affiliation: a The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom.
authors.forename: Timothy D
authors.initials: TD
authors.lastname: Warner
authors.affiliation: a The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom.
authors.forename: Paul C
authors.initials: PC
authors.lastname: Armstrong
authors.affiliation: a The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom.
authors.forename: Melissa V
authors.initials: MV
authors.lastname: Chan
authors.affiliation: a The William Harvey Research Institute, Barts and The London School of Medicine & Dentistry , Queen Mary University of London , London , United Kingdom.
authors.forename: Rebecca B
authors.initials: RB
authors.lastname: Knowles
mesh_terms: D001241:Aspirin / Q000494:pharmacology / Q000627:therapeutic use*; D001792:Blood Platelets / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D004730:Endothelium, Vascular / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D058921:Purinergic P2Y Receptor Antagonists / Q000494:pharmacology / Q000627:therapeutic use*; D013927:Thrombosis / Q000378:metabolism / Q000473:pathology / Q000517:prevention & control*
chemical_list: D010975:Platelet Aggregation Inhibitors; D058921:Purinergic P2Y Receptor Antagonists; D001241:Aspirin